InDevR, Inc., a life science tools company focused on developing and commercializing novel analytical technologies for biologic process development and monitoring, announced that Ms. Terry Salyer has joined the company as Chief Commercial Officer.
BOULDER, Colo., December 3, 2019 (Newswire.com) - InDevR, Inc., a life science tools company focused on developing and commercializing novel analytical technologies for biologic process development and monitoring, today announced that Ms. Terry Salyer has joined the company as Chief Commercial Officer. Terry has more than 20 years of extraordinary success in building commercial teams and driving revenue, both of which she will focus on for InDevR’s VaxArray and Cypher One product lines.
Kathy Rowlen, Ph.D., InDevR’s CEO, commented, “I am super excited to have Terry join our team and have no doubt that she will play a pivotal role in expanding our commercial reach. Her outstanding achievements at companies such as Unchained Labs, ProteinSimple, and ForteBio portend great things for InDevR and our mission to positively impact global health,” stated InDevR’s CEO, Dr. Kathy Rowlen.
Terry specializes in introducing novel technology to enable the biotech industry to move forward faster with higher quality data. Her sales experience includes building several high growth global sales teams in the life sciences tools marketplace. Prior to joining InDevR, Terry was Chief Commercial Officer at Unchained Labs, focusing on enabling faster testing in bioprocess development and growing revenue to $55 million in four years. At ProteinSimple, Terry doubled revenue as the Vice President of Worldwide Sales and helped create a corporate value of $300 million via the acquisition by Biotechne. While Terry was Vice President of Sales at ForteBio, she grew revenue to $27 million in four years before the successful sale to Pall Corporation. Earlier positions include Vice President of Worldwide Sales and Service at Eksigent Technologies, and Director of Sales at Molecular Devices.
Ms. Salyer commented, “I am delighted to work with the InDevR team to bring new analytical tools to vaccine development and manufacturing. Current laboratory methods in this area of research are slow, consume a lot of reagents, and need standardization. InDevR’s VaxArray platform will offer increased sensitivity and speed during bioprocess development and the Cypher One system will improve data quality during clinical evaluation. Helping our biopharma customers produce vaccines at lower cost and deliver them to market faster will benefit all of us.”
About InDevR—Based in Boulder, CO, InDevR is a life science tools company poised to significantly impact vaccine process optimization and manufacturing with powerful new protein characterization tools. The VaxArray® platform offers rapid multiplexed protein quantification for bioprocess development, improvement and monitoring, as well as identity and potency testing. The VaxArray Influenza product line includes off-the-shelf reagent kits for seasonal and pre-pandemic hemagglutinin, seasonal and pre-pandemic neuraminidase and nucleoprotein. The Cypher One system is an affordable automated reader for hemagglutination and hemagglutination inhibition assays. Both product lines offer unprecedented data integrity through digital records and 21CFR Part 11 ready software.
For more information about the company and products, please visit www.indevr.com or call (303) 402-9100.
Media Contact
Shannon Rodriguez, InDevR, Inc., (303) 402-9100
